peptide, dimer or composition as disclosed herein to the subject. In some examples, the peptide or dimer is administered in a therapeutically effective amount. In some examples, the disease of iron metabolism is an iron overload disease.

In one aspect, the present disclosure refers to the peptide or pharmaceutically acceptable salt or solvate thereof as disclosed herein or the composition as disclosed herein for use in the treatment of a disease of iron metabolism in a subject in need thereof, wherein the disease of iron metabolism is optionally selected from hereditary hemochromatosis, iron hemochromatosis, HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, thalassemia, thalassemia intermedia, alpha thalassemia, and β-thalassemia.

In one aspect, the present disclosure refers to use of the peptide or pharmaceutically acceptable salt or solvate thereof as disclosed herein or the composition as disclosed herein in the manufacture of a medicament for the treatment of a disease of iron metabolism in a subject in need thereof, wherein the disease of iron metabolism is optionally selected from hemochromatosis, hereditary hemochromatosis, HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, an iron overload disease, transfusional iron overload, thalassemia, thalassemia intermedia, alpha thalassemia, and β-thalassemia.